Synthetic Biology

Our Synthetic Biology research focuses on engineering biological systems to develop innovative biopharmaceuticals and delivery platforms. By combining advanced molecular biology, genetic engineering, and bioinformatics, we aim to create therapeutic solutions that address pressing medical challenges.

Our Synthetic Biology research is dedicated to designing and engineering biological systems for transformative pharmaceutical applications, driving the development of innovative therapies and delivery technologies.

Key Areas of Research:

Development of Monoclonal Antibodies (mAbs)

  • Engineering and optimizing monoclonal antibodies for enhanced specificity, stability, and therapeutic efficacy.
  • Designing antibodies for a wide range of applications, including cancer immunotherapy, infectious disease treatment, and autoimmune disorder management.

Drug-Conjugated Therapeutics

  • Developing antibody-drug conjugates (ADCs) by coupling mAbs with potent cytotoxic agents for targeted drug delivery.
  • Engineering conjugation systems to improve payload stability, controlled release, and selective action at disease sites.
  • Exploring innovative linker chemistries and conjugation strategies to expand the range of therapeutic applications.

Outer Membrane Vesicles (OMVs) from Bacteria

  • Harnessing bacterial OMVs as novel vaccine platforms and drug delivery systems.
  • Engineering OMVs to display antigens, deliver therapeutic molecules, and modulate immune responses.
  • Optimizing production methods for scalable and reproducible OMV generation.

Extracellular Vesicles (EVs) from Yeast

  • Engineering EVs to serve as natural, biocompatible vehicles for drug and nucleic acid delivery.
  • Modifying yeast to produce customized EVs for specific therapeutic applications.
  • Characterizing EV cargo and surface modifications to enhance targeting and uptake by diseased cells.

Pharmaceutical Applications

  • Translating synthetic biology innovations into scalable platforms for vaccine development, cancer therapeutics, and precision medicine.
  • Addressing key challenges in drug delivery, such as stability, immunogenicity, and biodistribution, to improve therapeutic outcomes.
  • Partnering with industry and clinical researchers to accelerate the pathway from bench to bedside.